RecruitingNCT06039241

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Prospective, Non-interventional, Observational Study for Multi-dimensional Assessment of Signs, Symptoms, Quality of Life and Disease Control of Long-term Treatment With Dupilumab in Patients With Atopic Dermatitis (≥6 Years)

Sponsor

Sanofi

Enrollment

900 participants

Start Date

Mar 7, 2023

Study Type

OBSERVATIONAL

Conditions

Atopic Dermatitis

Summary

This is a Prospective, non-interventional (NIS) observational study in patients (≥6 years) with atopic dermatitis (AD) receiving dupilumab for the prospective evaluation of signs and symptoms, quality of life and disease control. The aim of this NIS is the characterization of the AD patient population in Germany, receiving dupilumab under everyday conditions in terms of their medical history, socio-demographic and disease-related characteristics, associated atopic comorbidities and type 2 inflammation diseases, concomitant therapy as well as previous systemic and ongoing AD treatments. In addition to the therapeutic response rate at Month 6, the long-term efficacy of dupilumab at Month 12 and Month 24 will be assessed by additional outcomes by measuring disease control in AD patients using questionnaires such as Atopic Dermatitis Control Tool (ADCT) and Recap of Atopic Eczema (RECAP). In addition, this NIS aims to assess the dosing pattern of dupilumab for AD, including variations in dosing regimen, reason for dupilumab treatment initiation or discontinuation, or change in therapy and concomitant therapies and duration of treatment. In addition, the effect of dupilumab in adult and pediatric AD patients with associated atopic comorbidities or type-2 inflammation diseases are observed, which corresponds to the clinical care situation. Finally, this NIS aims to collect long-term safety data in adult, adolescent and pediatric AD patients treated with dupilumab. Individual observation period is 2 years or until dupilumab is discontinued. Visits will be scheduled according to standard of care.

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with atopic dermatitis. The study is currently recruiting participants at 55 locations. People eligible for this study include aged 6 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(55)

Investigational Site Number: 061

Aachen, Germany

Investigational Site Number: 092

Ahaus, Germany

Investigational Site Number: 066

Andernach, Germany

Investigational Site Number: 002

Berlin, Germany

Investigational Site Number: 003

Berlin, Germany

Investigational Site Number: 176

Berlin, Germany

Investigational Site Number: 077

Berlin, Germany

Investigational Site Number: 004

Berlin, Germany

Investigational Site Number: 174

Berlin, Germany

Investigational Site Number: 073

Berlin, Germany

Investigational Site Number: 059

Braunschweig, Germany

Investigational Site Number: 057

Buxtehude, Germany

Investigational Site Number: 028

Chemnitz, Germany

Investigational Site Number: 069

Cologne, Germany

Investigational Site Number: 072

Dresden, Germany

Investigational Site Number: 026

Dresden, Germany

Investigational Site Number: 032

Düren, Germany

Investigational Site Number: 043

Erlangen, Germany

Investigational Site Number: 064

Essen, Germany

Investigational Site Number: 184

Friedberg, Germany

Investigational Site Number: 055

Gera, Germany

Investigational Site Number: 007

Giessen, Germany

Investigational Site Number: 031

Gladbeck, Germany

Investigational Site Number: 078

Göttingen, Germany

Investigational Site Number: 087

Hamburg, Germany

Investigational Site Number: 088

Hamburg, Germany

Investigational Site Number: 020

Hamburg, Germany

Investigational Site Number: 086

Hamburg, Germany

Investigational Site Number: 169

Heidelberg, Germany

Investigational Site Number: 053

Heilbad Heiligenstadt, Germany

Investigational Site Number: 063

Jülich, Germany

Investigational Site Number: 186

Karlsruhe, Germany

Investigational Site Number: 016

Kiel, Germany

Investigational Site Number: 017

Kiel, Germany

Investigational Site Number: 183

Landsberg, Germany

Investigational Site Number: 038

Langenau, Germany

Investigational Site Number: 179

Leipzig, Germany

Investigational Site Number: 178

Mainz, Germany

Investigational Site Number: 185

Mainz, Germany

Investigational Site Number: 014

Mainz, Germany

Investigational Site Number: 013

Mannheim, Germany

Investigational Site Number: 018

Mölln, Germany

Investigational Site Number: 035

Mönchengladbach, Germany

Investigational Site Number: 050

München, Germany

Investigational Site Number: 076

Neubrandenburg, Germany

Investigational Site Number: 045

Nuremberg, Germany

Investigational Site Number: 042

Nuremberg, Germany

Investigational Site Number: 024

Oelde, Germany

Investigational Site Number: 082

Potsdam, Germany

Investigational Site Number: 172

Remscheid, Germany

Investigational Site Number: 177

Rostock, Germany

Investigational Site Number: 047

Wasserburg, Germany

Investigational Site Number: 019

Wismar, Germany

Investigational Site Number: 168

Wittlich, Germany

Investigational Site Number: 193

Wuppertal, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06039241

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT068992041 location

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT0680728137 locations

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT0723994710 locations

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT065643895 locations